|
|
|
|
 |
|
M&A of Local Pharmaceutical Companies |
|
China has about 4,000
local pharmaceutical companies accredited by China
GMP. In year 2005, about 15,000 licenses of generics
were granted to these domestic companies. M & A is
one of the key strategic tools for foreign companies
to establish or enhance their operation in China
with high efficiency, cost savings, and competitive
advantages. With its marketing research team, and
comprehensive data warehouse set up, LFE provides
the required expertise and experience in order to
achieve the screening of local merger / acquisition
candidates.
Key information LFE can provide to make a short list
of M & A candidates is as follows:
Corporate
|
|
|
Location of HQ,
subsidiaries, offices and plants |
|
|
Ownership structure, market capitalization and
development |
|
|
for public companies |
|
|
Business model in past and
present; business scope (TCM, |
|
|
OTC,API, FDF) |
|
Basic Financials |
|
|
Total sales revenue and structure (TCM, OTC, API, FDF)
|
|
|
Fixed assets |
|
|
Profitability |
|
Product portfolio and pipeline |
|
|
Therapeutic focus
|
|
|
Product portfolio and product sales |
|
|
RDL listing, hospital formulary
Overall R & D capability and
|
|
|
pipeline: products and
category |
|
Sales and distribution |
|
|
Geographical coverage: urban, province, national
|
|
|
Coverage of hospitals, clinics and pharmacies |
|
|
Sales force size
|
|
|
Distributor strategy |
|
|
Branding strategy |
|
Manufacturing /capabilityn |
|
|
Manufacturing location |
|
|
GMP and
HSE compliance |
|
| |
|
|
|
|
|
